<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62203">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02077036</url>
  </required_header>
  <id_info>
    <org_study_id>nervus11</org_study_id>
    <nct_id>NCT02077036</nct_id>
  </id_info>
  <brief_title>Narcolepsy - New Potential Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the study is to investigate the effect of a new, non-pharmacological
      method that may alleviate the symptoms of narcolepsy and thereby lead to a reduction in the
      use of medications with potentially serious side effects in patients with this disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind</study_design>
  <primary_outcome>
    <measure>Change in scale Epworth Sleep Scale (ESS)</measure>
    <time_frame>15-21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in ESS scale between baseline before treatment and at 15-21 days after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in multiple sleep latency test (MSLT)</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in MSLT (mean sleep latency, number of sleep onset rapid eye movement (SOREM), and mean SOREM latency) between registration at baseline and 14 days after treatment.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Narcolepsy</condition>
  <arm_group>
    <arm_group_label>Active medical device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive medical device</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Kinetic Oscillation Stimulation Device</intervention_name>
    <arm_group_label>Active medical device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Kinetic Oscillation Stimulation Device in placebo mode</intervention_name>
    <arm_group_label>Inactive medical device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Diagnosed with narcolepsy (diagnose code G47.4)

          -  16 - 60 years of age

          -  MSLT has shown hypersomnia (sleeping latency &lt; 8 min) &amp; 1 episode REM

          -  HLA-type associated with increased occurrence of narcolepsy

        Exclusion Criteria:

          -  Reduced cognitive function

          -  Other relevant organ disease (that could affect the study results or put the patient
             at risk)

          -  Ongoing bacterial infection in the nose

          -  Comorbidity that can increase the risk of bleeding

          -  Has received treatment with an implantable stimulator or other implantable product in
             the head and / or in the neck

          -  Known pronounced septal deviation

          -  Known allergy to polyvinylchloride or medicinal liquid paraffin

          -  Women not using adequate contraceptives

          -  Participated in a clinical investigational drug trial within the previous 30 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lars Hyllienmark, MD, PhD</last_name>
    <phone>+46-8-517 729 79</phone>
    <email>lars.hyllienmark@karolinska.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lars Hyllienmark, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Hyllienmark</investigator_full_name>
    <investigator_title>Associate professor, consultant in neurology and clinical neurophysiology</investigator_title>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Narcolepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
